Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on November 14, 2017. The filing serves to announce the company's financial results for the quarter ended September 30, 2017, which are detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input content.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2017, have been issued.
Guidance, Outlook, and Risks
The document includes standard legal disclaimers stating that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 Press Release, as they are absent from the 8-K cover text.
- Confirm the company's current name and ticker status, noting the discrepancy between the metadata ("Harrow, Inc.") and the registrant name in the filing ("Imprimis Pharmaceuticals, Inc.").
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are typical drivers for this company's valuation.